IP Library › Granted Patent US 7,550,440
Granted Patent B2
US 7,550,440 · App. 11/255,910 · Granted Jun 23, 2009

Topical application of ivermectin for the treatment of dermatological conditions/afflictions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,550,440
App. No.
11/255,910
Granted
Jun 23, 2009
Kind
B2
Abstract

Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

Claims (156)

1. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, the topical pharmaceutical emulsion which comprises:

Ivermectin

1.00

Glycerol

4.0

Acrylate C10-30 alkyl acrylate

0.2

crosspolymer

Methyl para-hydroxybenzoate

0.2

Disodium EDTA

0.05

Citric acid monohydrate

0.05

Isopropyl palmitate

4.0

Cetyl alcohol

3.5

Stearyl monostearate

2.5

Oleyl alcohol

2.0

Ceteareth-20

3.0

Sorbitan monostearate

2.0

Dimethicone 200 20 cs

0.5

Propyl para-hydroxybenzoate

0.1

Propylene glycol

2.0

Phenoxyethanol

1.0

10% sodium hydroxide

qs pH

Water

qs 100

as % by weight relative to the total weight of the emulsion.

2. A regime or regimen for the treatment of rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, the topical pharmaceutical emulsion which comprises:

Ivermectin

1.4

Glycerol

4.0

Acrylate C10-30 alkyl acrylate

0.2

crosspolymer

Methyl para-hydroxybenzoate

0.2

Disodium EDTA

0.05

Citric acid monohydrate

0.05

Isopropyl palmitate

4.0

Cetyl alcohol

3.5

Stearyl alcohol

2.5

Oleyl alcohol

2.0

Ceteareth-20

3.0

Sorbitan monostearate

2.0

Dimethicone 200 20 cs

0.5

Propyl para-hydroxybenzoate

0.1

Propylene glycol

2.0

Phenoxyethanol

1.0

10% sodium hydroxide

qs pH

Water

qs 100

as % by weight relative to the total weight of the emulsion.

3. The topically applicable, stable pharmaceutical emulsion comprising:

Ivermectin

1.00

Glycerol

4.0

Acrylate C10-30 alkyl acrylate

0.2

crosspolymer

Methyl para-hydroxybenzoate

0.2

Disodium EDTA

0.05

Citric acid monohydrate

0.05

Isopropyl palmitate

4.0

Cetyl alcohol

3.5

Stearyl alcohol

2.5

Oleyl alcohol

2.0

Ceteareth-20

3.0

Sorbitan monostearate

2.0

Dimethicone 200 20 cs

0.5

Propyl para-hydroxybenzoate

0.1

Propylene glycol

2.0

Phenoxyethanol

1.0

10% sodium hydroxide

qs pH

Water

qs 100

as % by weight relative to the total weight of the emulsion.

4. The topically applicable, stable pharmaceutical emulsion comprising:

Ivermectin

1.4

Glycerol

4.0

Acrylate C10-30 alkyl acrylate

0.2

crosspolymer

Methyl para-hydroxybenzoate

0.2

Disodium EDTA

0.05

Citric acid monohydrate

0.05

Isopropyl palmitate

4.0

Cetyl alcohol

3.5

Stearyl alcohol

2.5

Oleyl alcohol

2.0

Ceteareth-20

3.0

Sorbitan monostearate

2.0

Dimethicone 200 20 cs

0.5

Propyl para-hydroxybenzoate

0.1

Propylene glycol

2.0

Phenoxyethanol

1.0

10% sodium hydroxide

qs pH

Water

qs 100

as % by weight relative to the total weight of the emulsion.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Apr 26, 2021
From: NESTLÉ SKIN HEALTH SA
To: GALDERMA HOLDING SA
Reel/Frame 056045/0088 →
ASSET TRANSFER AGREEMENT Recorded Apr 26, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH SA
Reel/Frame 056048/0065 →